Relation between the tumor necrosis factor-α (TNF-α) gene and protein expression, and clinical, biochemical, and genetic markers: Age, body mass index and uric acid are independent predictors for an elevated TNF-α plasma level in a complex risk model

European Cytokine Network

Volumn 15, Issue 2, 2004, Pages 105-111

  Schulz, Susanne ^a,b   Schagdarsurengin, Undraga ^a   Suss, Thomas ^a,b   Müller Werdan, Ursula ^b   Werdan, Karl ^b   Gläser, Christiane ^a,c  

^a Inst of Hum Genet and Med Biol   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c Inst of Hum Genet and Med Biol   (Germany)

Author keywords

Clinical and biochemical parameters; Genetic background; mRNA level; Protein level; TNF

Indexed keywords

BIOCHEMICAL MARKER; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; PLASMINOGEN; TUMOR NECROSIS FACTOR ALPHA; URIC ACID;

ADULT; AGE DISTRIBUTION; ARTICLE; ATHEROSCLEROSIS; BLOOD CLOTTING; BODY MASS; CORRELATION ANALYSIS; DIABETES MELLITUS; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOLYSIS; GENE EXPRESSION; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HUMAN; HYPERTENSION; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NUCLEOTIDE SEQUENCE; OBESITY; PROMOTER REGION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REGRESSION ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; RNA TRANSLATION; SINGLE STRAND CONFORMATION POLYMORPHISM;

ADULT; AGE FACTORS; BIOLOGICAL MARKERS; BLOOD COAGULATION; BODY MASS INDEX; DIABETES MELLITUS; FEMALE; FIBRINOLYSIS; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MONOCYTES; OBESITY; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; RISK FACTORS; SEX FACTORS; TUMOR NECROSIS FACTOR-ALPHA; URIC ACID;

EUKARYOTA;

EID: 3242754291     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Benedict CA. 2003. Viruses and the TNF-related cytokines, an evolving battle. Cytokine Growth Factor Rev 14: 349.
2. McDevitt H, Munson S, Ettinger E, Wu A. 2002. Multiple roles for tumour necrosis factor-α and lymphotoxin α/β in immunity and autoimmunity. Arthritis Res 4: 141.
3. Wilson AG, di Giovine FS, Duff GW. 1995. Genetics of tumour necrosis factor-α in autoimmune, infectious, and neoplastic diseases. J Inflamm 45: 1.
4. Moriwaki Y, Yamamaoto T, Shibutani Y, Aoki E, Tsutsumi Z, Takahashi S, Okamura H, Koga M, Fukuchi M, Hada T. 2003. Elevated levels of interleukin-18 and tumor necrosis factor-alpha in serum of patients with type 2 diabetes mellitus: relationship with diabetic nephropathy. Metabol 52: 605.
5. Spranger J, Kroke A, Mohlig M, Hoffman K, Bergmann MM, Ristow M, Bœing H, Pfeiffer AF. 2003. Inflammatory cytokines and the risk to develop type 2 dibetes results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam study. Diabetes 52: 812.
6. Perry RT, Collins JS, Wiener H, Acton R, Go RCP. 2001. The role of TNF and its receptors in Alzheimer's disease. Neurobiol Aging 22: 873.
7. DePalma RG, Hayes VW, Cafferata HT, Mohammadpour HA, Chow BK, Zacharski LR, Hall MR. 2003. Cytokine signature in atherosclerotic claudicants. J Surg Res 111: 215.
8. Frangogiannis NG, Smith CW, Entman ML. 2002. The inflammatory response in myocardial infarction. Cardiovasc Res 53: 31.
9. Young JL, Libby P, Schonbeck U. 2002. Cytokines in the pathogenesis of atherosclerosis. Thromb Haemost 88: 554.
10. Suarez EC, Krishnan RR, Lewis JG. 2003. The relation of severity of depressive symptoms to monocyte-associated proinflammatory cytokines and chemokines in apparently healthy men. Psychosom Med 65: 362.
11. Stears AJ, Byrne CD. 2001. Adipocyte metabolism and the metabolic syndrome. Diab Obes Metab 3: 129.
12. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. 2001. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 280: E745.
13. Boekstegers P, Weidenhöfer S, Zell R, Pilz G, Holler E, Ertel W, Kapsner T, Redl H, Schlag G, Kaul M, Kempeni J, Stenzel R, Werdan K. 1994. Repeated administration of a F(ab′)2 fragment of an anti-tumor necrosis factor-α monoclonal antibody in patients with severe sepsis: effects on the cardiovascular system and cytokine levels. Shock 1: 237.
14. Dellinger RP. 2003. Inflammation and coagulation: implications for the septic patient. Clin Infect Dis 36: 1259.
15. Berk BC, Abe JI, Min W, Surapisitchat J, Yan C. 2001. Endothelial atheroprotective and anti-inflammatory mechanisms. Ann N Y Acad Sci 947: 93.
16. Thorne SA, Abbot SE, Stevens CR, Winyard PG, Mills PG, Blake DR. 1996. Modified low density lipoproteins and cytokines mediated monocyte adhesion to smooth muscle cells. Atherosclerosis 127: 167.
17. Friedl J, Puhlmann M, Bartlett DL, Libutti SK, Turner EN, Gnant MF, Alexander HR. 2002. Induction of permeability across endothelial cell monolayers tumor necrosis factor (TNF) occurs via a tissue factor-dependent mechanism: relationship between the procoagulant and permeability effects of TNF. Blood 100: 1334.
18. Ungvari Z, Csiszar A, Edwards JG, Kaminski PM, Wolin MS, Kaley G, Koller A. 2003. Increased superoxide production in coronary arteries in Hyperhomocysteinemia - Role of tumor necrosis factor-α, NAD(P)H oxidase, and inducible nitric oxidase synthase. Arterioscler Thromb Vasc Biol 23: 418.
19. Bruunsgaard H, Andersen Ranberg K, Jeune B, Pedersen AN, Skinhoj P, Pedersen BK. 1999. A high plasma concentration of TNF-alpha is associated with dementia in centenarians. J Gerontol A Biol Sci Med Sci 54: M357.
20. Paolisso G, Rizzo MR, Maziotti G, Tagliamonte MR, Gambardella A, Rotondi M, Carella C, Giugliano D, Varricchio M, D'Onofrio F. 1998. Advancing age and insulin resistance: role of plasma tumor necrosis factor-alpha. Am J Physiol 275: E294.
21. Bruun JM, Pedersen SB, Kristensen K, Richelsen B. 2002. Opposite regulation of interleukin-8 and tumor necrosis factor-alpha by weight loss. Obes Res 10: 499.
22. Mizia-Stec K, Zahorska-Markiewicz B, Mandecki T, Janowska J, Szulc A, Jastrzekbska-Maj E, Gasior Z. 2003. Hyperlipidaemias and plasma cytokines in patients with coronary artery disease. Acta Cardiol 58: 9.
23. Leyva F, Anker SD, Godsland IF, Teixeira M, Hellewell PG, Kox WJ, Poole-Wilson PA, Coats AJ. 1998. Uric acid in chronic heart failure: a marker of chronic inflammation. Eur Heart J 19: 1814.
24. Kroeger K, Carville KS, Abraham L. 1997. The -308 tumor necrosis factor-α promoter polymorphism effects transcription. Mol Immunol 34: 391.
25. Gonzalez S, Rodrigo L, Martinez-Borra J, Lopez-Vazquez A, Fuentes D, Nino P, Cadahia V, Saro C, dieguez A, Lopez-Larrea C. 2003. TNF-α -308 promoter polymorphism is associated with enhanced TNF-α production and inflammatory activity in Crohn's patients with fistulizing disease. Am J Gastroenterol 98: 1101.
26. Cuenca J, Cuchacivch M, Perez C, Ferreira L, Aguirre A, Schiattino J, Soto L, Cruzat A, Salazar-Onfray F, Aguillon JC. 2003. The -308 polymorphism in tumour necrosis factor (TNF) gene promoter region and ex vivo lipopolysaccharide-induced TNF expression and cytotoxic activity in Chilean patients with rheumatoid arthritis. Rheumatol 42: 308.
27. Hajeer AH, Hutchinson IV. 2001. Influence of TNF-α gene polymorphisms on TNF-α production and disease. Human Immunol 62: 1191.
28. Bemelman MHA, van Tits LJ, Buurman WA. 1996. Tumor necrosis factor: function, release and clearance. Critic Rev Immunol 16: 1.
29. Kajzel EL, van Krugten MV, Brinkman BM, Huizinga TW, van der Straaten T, Hazes JM, Ziegler-Heitbrock HW, Nedospasov SA, Breedveld FC, Verweij CL. 1998. Functional analysis of a human tumor necrosis fator alpha (TNF-alpha) promoter polymorphism related to joint damage in rheumatoid arthritis. Mol Med 4: 724.
30. D'Alfonso S, Richiardi PM. 1994. A polymorphic variation in a putative regulation box of the TNFA promoter region. Immunogenetics 39: 150.
31. Drouet C, Shakov AN, Jongeneel CV. 1991. Enhancers and transcription factors controlling the inducibility of the tumor necrosis factor-α promoter in primary macrophages. J Immunol 147: 1694.
32. Olexa P, Olexova M, Gonsorcik J, Tkac I, Kiselova J, Olejnikova M. 2002. Uric acid - a marker for systemic inflammatory response in patients with congestive heart failure? Wien Klin Wochenschr 114:211.
33. Rodriguez-Nunez A, Cid E, Rodriguez-Garcia J, Camina F, Rodriguez-Segade S, Castro-Gago M. 2001. Concentrations of nucleotides, nucleosides, purine bases, oxypurines, uric acid, and neuron-specific enolase in the cerebrsosinal fluid of children with sepsis. J Child Neurol 16: 704.
34. Voros G, Maquoi E, Collen D, Lijnen HR. 2004. Influence of membrane-bound tumor necrosis factor (TNF)-alpha on obesity and glucose metabolism. J Thromb Haemost 2: 507.
35. van Leeuwen HJ, Heezius EC, Dallinga GM, van Strijp JA, Verhoef J, van Kessel KP. 2003. Lipoprotein metabolism in patients with severe sepsis. Crit Care Med 5: 1359.
36. Barter P. 2002. Effects of inflammation on high-density lipoproteins. Arterioscler Thromb Vasc Biol 22: 1062.
37. Fan J, Watanabe T. 2003. Inflammatory reactions in the pathogenesis of atherosclerosis. J Atheroscler Thromb 10: 63.
38. Calabresi L, Rossoni G, Gomaraschi M, Sisto F, Berti F, Franceschini G. 2003. High-density lipoproteins protect isolated rat hearts from ischemia-reperfusion injury by reducing cardiac tumor necrosis factor-α content and enhancing prostaglandin release. Circ Res 92: 330.
39. Cauza E, Cauza K, Hanusch-Enserer U, Etemad M, Dunky A, Kostner K. 2002. Intravenous anti TNF-α antibody therapy leads to elevated triglyceride and reduced HDL-cholesterol levels in patients with rheumatoid and psoriatic arthritis. Wien Klin Wochenschr 114: 1004.
40. Muth H, Maus U, Wygrecka M, Lohmeyer J, Grimmiger F, Seeger F, Gunther A. 2004. Pro- and antifibrinolytic properties of human pulmonary microvascular versus artery endothelial cells: impact of endotoxin and tumor necrosis factor-alpha. Crit Care Med 32: 217.
41. van Hinsbergh VW, Bauer KA, Kooistra T, Kluft C, Dooijewaard G, Sherman ML, Nieuwenhuizen W. 1990. Progress of fibrinolysis during tumor necrosis factor infusion in humans. Concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation products. Blood 76: 2284.
42. Silverman P, Goldsmith GH, Spitzer TR, Rehmus EH, Berger NA. 1990. Effect of tumor necrosis factor on the human fibrinolytic system. J Clin Oncol 8: 468.
43. Ceydeli A, Condon MR, Siegel JH. 2003. The septic abscess wall: a cytokine-generating organ associated with portal venous cytokinemia, hepatic outflow fibrosis, sinusoidal congestion, inflammatory cell sequestration, hepatocellular lipid deposistion, and focal cell death. Shock 20: 74.
44. Ernst E, Resch KL. 1993. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 118: 956.
45. Bruunsgaard H, Pedersen M, Pedersen BK. 2001. Aging and proinflammatory cytokines. Curr Opin Hematol 8: 131.